News
June 10, 2026
IR
Supplementary Materials of FY26 Q3 Consolidated Financial Results 
June 10, 2026
IR
[Summary] Consolidated Financial Results for the Nine Months Ended April 30, 2026 (Under Japanese GAAP)
April 30, 2026
R&D
PharmaGABA® New Scientific Study Published in Leading International Journal - Accelerating Global Expansion and Adoption in the Food & Beverage Category -
April 22, 2026
Media
Pharma Foods Certified as 2026 Health & Productivity Management Outstanding Organization ― Fourth consecutive year of recognition; Group-wide commitment to "KENKO Investment" ―
April 6, 2026
R&D
Pharma Foods Co., Ltd. Acquires Exclusive Rights to Advance First-in-Class Adrenomedullin Program for CADASIL Across Key Asian Markets
March 23, 2026
IR
Supplementary Materials of Consolidated Financial Results for the Six Months Ended January 31, 2026
March 13, 2026
IR
Notice Regarding Revision of Full-Year Financial Results Forecast for the Fiscal Year Ending July 2026
March 13, 2026
IR
[Summary]Consolidated Financial Results for the Six Months Ended January 31, 2026 (Based on Japanese GAAP)
February 16, 2026
IR
Notice Concerning Dividends of Surplus (Interim Dividend)
December 11, 2025
IR
Supplementary Materials of Consolidated Financial Results for the Three Months Ended October 31 2025
June 10, 2026
IR
[Summary] Consolidated Financial Results for the Nine Months Ended April 30, 2026 (Under Japanese GAAP)
April 30, 2026
R&D
PharmaGABA® New Scientific Study Published in Leading International Journal - Accelerating Global Expansion and Adoption in the Food & Beverage Category -
April 22, 2026
Media
Pharma Foods Certified as 2026 Health & Productivity Management Outstanding Organization ― Fourth consecutive year of recognition; Group-wide commitment to "KENKO Investment" ―
April 6, 2026
R&D
Pharma Foods Co., Ltd. Acquires Exclusive Rights to Advance First-in-Class Adrenomedullin Program for CADASIL Across Key Asian Markets
March 23, 2026
IR
Supplementary Materials of Consolidated Financial Results for the Six Months Ended January 31, 2026
March 13, 2026
IR
Notice Regarding Revision of Full-Year Financial Results Forecast for the Fiscal Year Ending July 2026
March 13, 2026
IR
[Summary]Consolidated Financial Results for the Six Months Ended January 31, 2026 (Based on Japanese GAAP)
February 16, 2026
IR
Notice Concerning Dividends of Surplus (Interim Dividend)
December 11, 2025
IR
Supplementary Materials of Consolidated Financial Results for the Three Months Ended October 31 2025